UBS Group
AVIR icon

UBS Group’s Atea Pharmaceuticals AVIR Stock Holding History

UBS Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$439K Sell
94,507
-15,443
-14% -$76.8K ﹤0.01% 6324
2026
Q1 		$592K Sell
109,950
-82,590
-43% -$379K ﹤0.01% 5966
2025
Q4 		$687K Buy
192,540
+90,329
+88% +$287K ﹤0.01% 5875
2025
Q3 		$296K Sell
102,211
-7,213
-7% -$24.6K ﹤0.01% 6441
2025
Q2 		$394K Buy
109,424
+45,856
+72% +$137K ﹤0.01% 6209
2025
Q1 		$190K Sell
63,568
-9,345
-13% -$29.2K ﹤0.01% 6593
2024
Q4 		$244K Sell
72,913
-5,478
-7% -$18.2K ﹤0.01% 6330
2024
Q3 		$263K Buy
78,391
+6,812
+10% +$24.7K ﹤0.01% 5676
2024
Q2 		$237K Sell
71,579
-32,491
-31% -$121K ﹤0.01% 5549
2024
Q1 		$420K Sell
104,070
-3,576
-3% -$14K ﹤0.01% 5336
2023
Q4 		$328K Buy
107,646
+50,605
+89% +$153K ﹤0.01% 5431
2023
Q3 		$171K Sell
57,041
-41,823
-42% -$142K ﹤0.01% 5465
2023
Q2 		$370K Buy
98,864
+46,051
+87% +$172K ﹤0.01% 5073
2023
Q1 		$177K Sell
52,813
-22,422
-30% -$91K ﹤0.01% 5487
2022
Q4 		$362K Buy
75,235
+59,818
+388% +$303K ﹤0.01% 4969
2022
Q3 		$88K Buy
15,417
+4,166
+37% +$31.9K ﹤0.01% 5812
2022
Q2 		$80K Sell
11,251
-17,754
-61% -$121K ﹤0.01% 5586
2022
Q1 		$209K Sell
29,005
-75,716
-72% -$514K ﹤0.01% 5318
2021
Q4 		$935K Buy
104,721
+41,034
+64% +$639K ﹤0.01% 4451
2021
Q3 		$2.23M Sell
63,687
-611,422
-91% -$17M ﹤0.01% 3485
2021
Q2 		$14.5M Buy
675,109
+671,483
+18,519% +$20.2M ﹤0.01% 1734
2021
Q1 		$224K Sell
3,626
-6,944
-66% -$469K ﹤0.01% 5404
2020
Q4 		$442K Buy
+10,570
New +$341K ﹤0.01% 4693

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

UBS Group's AVIR Position: Q2 2026 in Review

UBS Group reduced its Atea Pharmaceuticals (AVIR) stake by 14% in Q2 2026, selling an estimated $76.8K and leaving 94,507 shares worth $439K. The position accounts for ﹤0.01% of the portfolio, ranked #6324.

UBS Group first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $14.5M in Q2 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • UBS Group held 94,507 shares of Atea Pharmaceuticals worth $439K as of Q2 2026.
  • UBS Group sold 15,443 Atea Pharmaceuticals shares in Q2 2026, an estimated $76.8K.
  • Atea Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6324 holding.
  • UBS Group first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • UBS Group's Atea Pharmaceuticals position peaked at $14.5M in Q2 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.